<DOC>
	<DOCNO>NCT00003099</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use fenretinide tamoxifen surgery may effective way prevent recurrence development breast cancer . PURPOSE : Randomized phase II trial study effectiveness fenretinide tamoxifen give surgery treat woman breast cancer .</brief_summary>
	<brief_title>Chemoprevention Therapy Plus Surgery Treating Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility identify surrogate endpoint biomarkers woman breast ductal carcinoma situ associate neoplastic preneoplastic lesion . II . Determine whether treatment fenretinide tamoxifen administer daily cause significant modulation propose surrogate endpoint biomarkers patient population . OUTLINE : This randomize , placebo control study . Patients stratify accord histological diagnosis ( hyperplasia v carcinoma ) . All patient undergo core biopsy fine needle aspiration index lesion assign randomly treatment arm . Arm I receive tamoxifen fenretinide daily . Arm II receive placebo daily . Both arm continue 14-28 day , definitive surgery second biopsy perform . PROJECTED ACCRUAL : A total 100 patient accrue study , 50 patient per arm .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Retinamide</mesh_term>
	<mesh_term>Fenretinide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Mammogram highly suspicious ductal carcinoma situ early invasive carcinoma Branching linear microcalcifications cluster distribute segmentally breast without associate palpable mammographic mass Palpable thicken nipple discharge allow At least 5 mm area calcification contain enough calcium core biopsy Small palpable carcinoma ( T1 T2 ) palpable axillary lymph node ( N0 ) No definitive local therapy Atypical hyperplasia ( ductal lobular ) and/or carcinoma initial diagnostic biopsy Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Over 18 Sex : Female Menopausal status : Not specify Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count great 1500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Cardiovascular : No uncontrolled congestive heart failure Other : Fasting serum triglyceride le 400 mg/dL Fertile patient must use effective contraception one year complete fenretinide therapy No concurrent serious illness infection , e.g. , septicemia No prior thromboembolic disease No prior degenerative retinal disease PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 5 year since prior chemotherapy Endocrine therapy : At least 12 month since prior tamoxifen therapy No concurrent estrogen therapy At least 3 month since prior anabolic steroid Radiotherapy : No prior radiotherapy chest breast Surgery : See Disease Characteristics Other : No vitamin A supplementation great 25,000 IU At least 12 month since prior retinoid therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Fenretinide</keyword>
	<keyword>Chemoprevention Therapy</keyword>
	<keyword>N- ( 4-hydroxyphenyl ) Retinamide</keyword>
	<keyword>4-HPR</keyword>
	<keyword>Breast Neoplasia</keyword>
	<keyword>Diagnostic Core Biopsy</keyword>
	<keyword>Surgery</keyword>
</DOC>